|
|
Post by mango on Jan 19, 2021 13:11:01 GMT -5
Do y’all think RLS will do an IPO?
|
|
|
|
Post by visser on Jan 19, 2021 13:22:40 GMT -5
I think they are connected to Silver Spike, SSPKU which has recently doubled. Not sure if they'll be bought by them or what...
|
|
|
|
Post by derekewhitlock on Jan 19, 2021 13:46:39 GMT -5
Well, there is definitely a connection:
Orrin Devinsky
DIRECTOR
Orrin Devinsky is Chief Medical Officer of Receptor Life Sciences, Inc. He is also on the board of Engage Therapeutics, Inc. and Silver Spike Acquisition Corp. and Professor at New York University School of Medicine.
He received a graduate degree from Yale University, an undergraduate degree from Yale College and a doctorate from Harvard Medical School.
|
|
|
|
Post by mango on Jan 19, 2021 14:01:31 GMT -5
Devinsky was also most recently with GW Pharma.
|
|
|
|
Post by brentie on Jan 19, 2021 15:14:23 GMT -5
|
|
|
|
Post by boca1girl on Feb 3, 2021 8:32:27 GMT -5
|
|
|
|
Post by longliner on Feb 10, 2021 4:41:39 GMT -5
As has been suggested on other boards, were RLS to go public using a SPAC (Special purpose acquisition company) potentially Silver Spike (SSPK) / Weed Maps and
Mannkind were to have a % ownership stake in the Company for RLS living "rent free" on MNKD shareholders backs, we would immediately benefit from the
explosive growth in that industry. Silver Spike is one example of several available SPAC options. Just some early morning musing on my part.
|
|
|
|
Post by mango on Feb 10, 2021 12:39:54 GMT -5
GW has the only botanical FDA approved drug. Meaning it is the only FDA approved product on the market that is from whole plant Cannabis. The others are synthetic and single molecule. |
|
|
|
Post by mango on Feb 10, 2021 23:20:43 GMT -5
Our Cannabis partner, Receptor Life Sciences, recently received FDA guidance for the development of RLS 103, designed for the treatment of Acute Panic Attack, by using MannKind’s Technosphere technology and inhalation devices to develop a First In Class FDA approved inhaled Cannabidiol Technosphere treatment option for Acute Panic Attack. Ahead of the curve, eh?  |
|
|
|
Post by akemp3000 on Feb 11, 2021 5:14:08 GMT -5
Talk about right time, right place and hitting the nail on the head, RLS seems to be all over it. I'm wondering what will trigger the first of several significant milestone payments from RLS to Mannkind. The preIND and FDA guidance is certainly a good step and it's noted that RLS considers this to be a "significant milestone".
“Alignment on a clear 505(b)(2) development pathway for RLS103 is a significant milestone for the company,” said Andrea Leone-Bay, PhD, Chief Scientific Officer of RLS. “Currently no immediate-acting products are available for panic attacks, so RLS103 has the potential to be First-in-Class.
|
|
|
|
Post by itellthefuture777 on Feb 24, 2021 17:38:45 GMT -5
|
|
|
|
Post by kite on Feb 24, 2021 21:47:21 GMT -5
Receptor Life Sciences Receives FDA Guidance for Development of RLS 103, Designed for the Treatment of Acute Panic Attack January 11, 2021 08:00 AM Eastern Standard Time SEATTLE--(BUSINESS WIRE)--Receptor Life Sciences (RLS) today announced the completion of a pre-investigational new drug (preIND) meeting with the U.S. Food and Drug Administration (FDA). The meeting resulted in clear guidance on the regulatory requirements for the development and approval of RLS103 under section 505(b)(2). RLS103 is an investigational inhaled cannabidiol (CBD) designed for the treatment of acute panic attack. “Alignment on a clear 505(b)(2) development pathway for RLS103 is a significant milestone for the company” Tweet this “Alignment on a clear 505(b)(2) development pathway for RLS103 is a significant milestone for the company,” said Andrea Leone-Bay, PhD, Chief Scientific Officer of RLS. “Currently no immediate-acting products are available for panic attacks, so RLS103 has the potential to be First-in-Class. We look forward to continuing our dialogue with the FDA and have initiated our IND-enabling studies.” Panic disorder affects approximately 5.4 million adults (2.7% of the population) in the U.S., according to the National Institute of Mental Health. Benzodiazepines are the most common treatment for panic despite their well-known undesirable side effects, including dependence, sedation, and tolerance. An inhaled CBD formulation holds the potential to treat panic in a safe, effective, and convenient manner. RLS103 is a drug-device combination product based on the Technosphere® dry powder inhalation system licensed from MannKind Corporation. The FDA’s 505(b)(2) pathway was established in 1984 to accelerate the development of promising new medications by allowing the use of data based on previously approved drugs. About Receptor Life Sciences Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval see: www.ReceptorLife.com. Contacts For Media: David Sheon dsheon@whitecoatstrategies.com 202.422.6999 |
|
|
|
Post by sportsrancho on Mar 31, 2021 17:56:46 GMT -5
|
|
|
|
Post by prcgorman2 on Apr 1, 2021 6:13:50 GMT -5
TSTHC! (In varying concentrations including low dose based on Indica might make a popular product.)
|
|
|
|
Post by prcgorman2 on Apr 1, 2021 6:15:11 GMT -5
This is also more interesting because “recreational” use without prescription, just like vaping, is a possibility (although I assume it is an exceedingly remote possibility).
|
|
